Molecular characteristics of the gyrA gene among rifampicin-resistant Mycobacterium tuberculosis isolates
Main Article Content
Keywords
gyrA Gene Mutation, MDR-TB, Fluoroquinolone Resistance, Rifampicin Resistance
Abstract
Background: Drug-resistant tuberculosis (TB) remains a public health threat, especially during this pandemic. Meanwhile, fluoroquinolone is used as a second-line multidrug-resistant TB (MDR-TB) treatment since this drug was previously prescribed for respiratory, urinary, and genital tract infections. However, unregulated and excessive use of fluoroquinolones leads to resistance.
Methods: The design of this study is a descriptive observational study with a cross sectional approach. This study aims to determine the pattern of gyrA gene mutation in fluoroquinolone resistance among rifampicin-resistant Mycobacterium tuberculosis isolates during the COVID-19 pandemic in Sumatra, Indonesia. The Mycobacterium tuberculosis isolates were stored in the Palembang Health Center Laboratory as the referral laboratory in Sumatra from January to December 2020. Out of the 233 isolates that were tested phenotypically by BACTEC MGIT, 8 isolates of fluoroquinolone resistance (ofloxacin or moxifloxacin or both) were obtained and sequenced using an ABI PRISM 3730XL analyzer for Single Nucleotide Polymorphism analysis (SNP).
Results: Among the six fluoroquinolone-resistant Mycobacterium tuberculosis isolates, the gyrA mutations were identified in 5/6 isolates (84%), A90V (34%), D94A (16%), and D94G (34%), while 1/6 isolates (16%) had no mutation in gyrA gene among Mycobacterium tuberculosis that were fluoroquinolone resistance.
Conclusion: The gyrA gene mutation in fluoroquinolone resistance among rifampicin-resistant Mycobacterium tuberculosis was commonly present in codon 90 (2/6 isolates =32%) and 94 (3/6 isolates=68%).
References
2. Rufai SB, Kumar P, Singh A, Prajapati S, Balooni V, Singh S. Comparison of Xpert MTB/RIF with Line Probe Assay for Detection of Rifampin-Monoresistant Mycobacterium tuberculosis. Journal of Clinical Microbiology. 2014;52(6):1846–52.
3. Bakułaa Z, Napiórkowskab A, Kamińskia M, Augustynowicz-Kopeć E, Zwolskab Z, Bieleckia J, et al. Second-line Anti-Tuberculosis Drug Resistance and Its Genetic Determinants in MultidrugResistant Mycobacterium Tuberculosis Clinical Isolates. Journal of Microbiology, Immunology and Infection. 2015;00747–1(15):S1684-1182.
4. World Heath Organization. Global Tuberculosis Report 2020. Geneva: World Health Organization; 2020. 23–24 p.
5. Ministry of Health. InfoDATIN Tuberkulosis. Jakarta Selatan: Ministry of Health Republic Indonesia; 2018.
6. Singh P, Jain A, Dixit P, Prakash S, Jaiswal I, Venkatesh V, et al. A novel gyrB gene Mutation in Fluoroquinolone Resistant Clinical Isolates of Mycobacterium Tuberculosis. In: 2nd International Science Symposium on HIV and Infectious Diseases. Chennai: BMC Infectious Diseases; 2014.
7. Yin X, Yu Z. Mutation Characterization of gyrA and gyrB Genes in Levofloxacin-resistant Mycobacterium Tuberculosis Clinical Isolates from Guangdong Province in China. Journal of Infection. 2010;61:150–4.
8. Brossier F, Guindo D, Pham A, Reibel F, Sougakoff W, Veziris N, et al. Performance of the New Version (v2.0) of the GenoType MTBDRsl Test for Detection of Resistance to Second-Line Drugs in MultidrugResistant Mycobacterium tuberculosis Complex Strains. Journal of Clinical Microbiology. 2016;54(6):1573–80.
9. Kusumaningrum D, Mertaniasih NM, Wiqoyah N. Detection of gyrA Gene Mutation Region in Fluoroquinolone Resistant M. tuberculosis Isolate From Surabaya Indonesia. Folia Medica Indonesiana. 2014;50(3):139–42.
10. Lau RWT, Ho P-L, Kao RYT, Yew W-W, Lau TCK, Cheng VCC, et al. Molecular Characterization of Fluoroquinolone Resistance in Mycobacterium tuberculosis: Functional Analysis of gyrA Mutation at Position 74. Antimicrobial Agents and Chemotherapy. 2011;55(2):608–14.
11. Takiff HE, Salazar L, Guerrero C, Philipp W, Huang WM, Kreiswirth B, et al. Cloning and Nucleotide Sequence of Mycobacterium tuberculosis gyrA and gyrB Genes and Detection of Quinolone Resistance Mutations. Antimicrobial Agents and Chemotherapy. 1994;38(4):773–80.
12. Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, Dean NC, et al. Infectious Diseases Society of America/American Thoracic Society Consensus Guidelines on theManagement of Community-Acquired Pneumoniain Adults. Clinical Infectious Diseases. 2007;44(2):27–72.
13. Devasia RA, Blackman A, Gebretsadik T, Griffin M, Shintani A, May C, et al. Fluoroquinolone Resistance in Mycobacterium tuberculosis The Effect of Duration and Timing of Fluoroquinolone Exposure. American Journal of Respiratory and Critical Care Medicine. 2009;180:366–70.
14. Feng L, Mundy JEA, Stevenson CEM, Mitchenall LA, Lawson DM, Mi K, et al. The Pentapeptide-repeat Protein, MfpA, Interacts with Mycobacterial DNA Gyrase as a DNA T-segment Mimic. In: Proceeding National Academy Science USA. 2021.
15. Hegde SS, Vetting MW, Roderick SL, Mitchenall LA, Maxwell A, Takiff HE, et al. A fluoroquinolone resistance protein from Mycobacterium tuberculosis that mimics DNA. Science. 2005;308(5727):1480–3.
16. Melly G, Purdy GE. MmpL Proteins in Physiology and Pathogenesis of M. tuberculosis. Microorganisms. 2019;7(70):1–16.
17. World Health Organization. Global Laboratory Initiative. Geneva: World Health Organization; 2018.
18. Gao Y, Zhang Z, Deng J, Mansjo M, Ning Z, Li Y, et al. Multi-Center Evaluation of GenoType MTBDRsl Line Probe Assay for Rapid Detection of pre-XDR and XDR Mycobacterium Tuberculosis in China. Journal of Infection. 2018;4453(18).
19. Singhal R, Reynolds PR, Marola JL, Epperson LE, Arora J, Sarin R, et al. Sequence Analysis of Fluoroquinolone Resistance-Associated Genes gyrA and gyrB in Clinical Mycobacterium tuberculosis Isolates from Patients Suspected of Having Multidrug-Resistant Tuberculosis in New Delhi, India. Journal of Clinical Microbiology. 2016;54(9):2298–305.
20. Chen J, Chen Z, Li Y, Xia W, Chen X, Chen T, et al. Characterization of gyrA and gyrB mutations and fluoroquinolone resistance in Mycobacterium tuberculosis clinical isolates from Hubei Province, China. The Brazilian Journal of Infectious Diseases. 2012;16(2):136–41.
21. Kabir S, Tahir Z, Mukhtar N, Sohail M, Saqalein M, Rehman A. Fluoroquinolone resistance and mutational profile of gyrA in pulmonary MDR tuberculosis patients. BMC Pulmonary Medicine. 2020;20(138):1–6.
22. Farhat MR, Jacobson KR, Franke MF, Kaur D, Sloutsky A, Mitnick CD, et al. Gyrase Mutations Are Associated with Variable Levels of Fluoroquinolone Resistance in Mycobacterium tuberculosis. Journal of clinical microbiology. 2016/01/13. 2016;54(3):727–33.
23. Chien J-Y, Chiu W-Y, Chien S-T, Chiang C-J, Yu C-J, Hsueh P-R. Mutations in gyrA and gyrB among Fluoroquinolone- and MultidrugResistant Mycobacterium tuberculosis Isolates. Amtimicrobial Agents and Chemotherapy. 2016;60(4):2090–6.
24. Ioerger TR, Feng Y, Ganesula K, Chen X, Dobos KM, Fortune S, et al. Variation among Genome Sequences of H37Rv Strains of Mycobacterium tuberculosis from Multiple Laboratories. Journal of Bacteriology. 2010;192(14):3645–53.
25. Barreda-García S, González-Álvarez MJ, de-Los-Santos-Álvarez N, Palacios-Gutiérrez JJ, Miranda-Ordieres AJ, Lobo-Castañón MJ. Attomolar quantitation of Mycobacterium tuberculosis by asymmetric helicase-dependent isothermal DNA-amplification and electrochemical detection. Biosensors & bioelectronics. 2015;68:122–8.